{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,2]],"date-time":"2026-10-02T02:17:12Z","timestamp":1790907432419,"version":"4.1.0"},"reference-count":77,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,7,30]],"date-time":"2026-07-30T00:00:00Z","timestamp":1785369600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100001003","name":"Boehringer Ingelheim Corp USA","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100001003","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["cancertreatmentreviews.com","clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Cancer Treatment Reviews"],"published-print":{"date-parts":[[2026,9]]},"DOI":"10.1016\/j.ctrv.2026.103195","type":"journal-article","created":{"date-parts":[[2026,7,26]],"date-time":"2026-07-26T17:26:42Z","timestamp":1785086802000},"page":"103195","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":3,"special_numbering":"C","title":["Understanding extrapulmonary neuroendocrine carcinomas: Survival, prognosis, and patient quality of life"],"prefix":"10.1016","volume":"149","author":[{"given":"Nitya","family":"Raj","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lauren A.","family":"Byers","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ctrv.2026.103195_bb0005","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1007\/s12022-022-09708-2","article-title":"Overview of the 2022 WHO classification of neuroendocrine neoplasms","volume":"33","author":"Rindi","year":"2022","journal-title":"Endocr Pathol"},{"key":"10.1016\/j.ctrv.2026.103195_bb0010","doi-asserted-by":"crossref","first-page":"1770","DOI":"10.1038\/s41379-018-0110-y","article-title":"A common classification framework for neuroendocrine neoplasms: an International Agency for Research on Cancer (IARC) and World Health Organization (WHO) expert consensus proposal","volume":"31","author":"Rindi","year":"2018","journal-title":"Mod Pathol"},{"key":"10.1016\/j.ctrv.2026.103195_bb0015","doi-asserted-by":"crossref","first-page":"807","DOI":"10.1002\/cncr.31124","article-title":"Comparative study of lung and extrapulmonary poorly differentiated neuroendocrine carcinomas: a SEER database analysis of 162,983 cases","volume":"124","author":"Dasari","year":"2018","journal-title":"Cancer"},{"key":"10.1016\/j.ctrv.2026.103195_bb0020","doi-asserted-by":"crossref","DOI":"10.3390\/jcm14072264","article-title":"Clinicopathological characteristics of extrapulmonary neuroendocrine carcinomas: treatment responses and survival outcomes: single-center experience","volume":"14","author":"Mu\u011flu","year":"2025","journal-title":"J Clin Med"},{"key":"10.1016\/j.ctrv.2026.103195_bb0025","doi-asserted-by":"crossref","DOI":"10.1530\/ERC-19-0483","article-title":"Extrapulmonary poorly differentiated NECs, including molecular and immune aspects","volume":"27","author":"McNamara","year":"2020","journal-title":"Endocr Relat Cancer"},{"key":"10.1016\/j.ctrv.2026.103195_bb0030","doi-asserted-by":"crossref","first-page":"182","DOI":"10.1111\/his.13975","article-title":"The 2019 WHO classification of tumours of the digestive system","volume":"76","author":"Nagtegaal","year":"2020","journal-title":"Histopathology"},{"key":"10.1016\/j.ctrv.2026.103195_bb0035","doi-asserted-by":"crossref","first-page":"804","DOI":"10.1093\/ajcp\/aqaf013","article-title":"Histopathologic and genetic distinction of well-differentiated grade 3 neuroendocrine tumor versus poorly-differentiated neuroendocrine carcinoma in high-grade neuroendocrine neoplasms","volume":"163","author":"Sun","year":"2025","journal-title":"Am J Clin Pathol"},{"key":"10.1016\/j.ctrv.2026.103195_bb0040","doi-asserted-by":"crossref","first-page":"724","DOI":"10.1210\/endrev\/bnad006","article-title":"Advances in the treatment of gastroenteropancreatic neuroendocrine carcinomas: are we moving forward?","volume":"44","author":"Garcia-Carbonero","year":"2023","journal-title":"Endocr Rev"},{"key":"10.1016\/j.ctrv.2026.103195_bb0045","first-page":"14","article-title":"Treatment strategies for advanced neuroendocrine neoplasms: current status and future prospects","volume":"22","author":"Ye","year":"2025","journal-title":"Cancer Biol Med"},{"key":"10.1016\/j.ctrv.2026.103195_bb0050","doi-asserted-by":"crossref","DOI":"10.3389\/fendo.2025.1635630","article-title":"Clinical characteristics and survival outcomes of extrapulmonary neuroendocrine carcinomas: a retrospective study","volume":"16","author":"Xu","year":"2025","journal-title":"Front Endocrinol (Lausanne)"},{"key":"10.1016\/j.ctrv.2026.103195_bb0055","doi-asserted-by":"crossref","DOI":"10.1016\/j.eclinm.2023.102015","article-title":"NET-02: a randomised, non-comparative, phase II trial of nal-IRI\/5-FU or docetaxel as second-line therapy in patients with progressive poorly differentiated extra-pulmonary neuroendocrine carcinoma","volume":"60","author":"McNamara","year":"2023","journal-title":"EClinicalMedicine"},{"key":"10.1016\/j.ctrv.2026.103195_bb0060","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejca.2024.114129","article-title":"A randomized phase II trial of Captem or Folfiri as second-line therapy in neuroendocrine carcinomas","volume":"208","author":"Bongiovanni","year":"2024","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.ctrv.2026.103195_bb0065","doi-asserted-by":"crossref","first-page":"1999","DOI":"10.1158\/1078-0432.CCR-21-3058","article-title":"Expanding therapeutic opportunities for extrapulmonary neuroendocrine carcinoma","volume":"28","author":"Frizziero","year":"2022","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.ctrv.2026.103195_bb0070","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1093\/oncolo\/oyab039","article-title":"Survival according to primary tumor location, stage, and treatment patterns in locoregional Gastroenteropancreatic high-grade neuroendocrine carcinomas","volume":"27","author":"Dasari","year":"2022","journal-title":"Oncologist"},{"key":"10.1016\/j.ctrv.2026.103195_bb0075","doi-asserted-by":"crossref","DOI":"10.3390\/jcm12247715","article-title":"Extrapulmonary neuroendocrine carcinomas: current management and future perspectives","volume":"12","author":"Stumpo","year":"2023","journal-title":"J Clin Med"},{"key":"10.1016\/j.ctrv.2026.103195_bb0080","doi-asserted-by":"crossref","unstructured":"Benini L, Gervaso L, Frassoni S, Bagnardi V, Cella CA, Algeri L, et al. Clinical\/pathological features and survival outcomes of extrapulmonary neuroendocrine carcinomas: a retrospective single-center series. J Neuroendocrinol 2025;n\/a:e70057. Doi: https:\/\/doi.org\/10.1111\/jne.70057.","DOI":"10.1111\/JNE.70057\/v4\/response1"},{"key":"10.1016\/j.ctrv.2026.103195_bb0090","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.2026.44.16_suppl.e16310","article-title":"Real-world patient characteristics, treatment patterns and clinical outcomes in patients diagnosed with extra-pulmonary neuroendocrine carcinoma (epNEC): a non-interventional multimodal database analysis in the US","volume":"44","author":"Vijayvergia","year":"2026","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ctrv.2026.103195_bb0085","doi-asserted-by":"crossref","DOI":"10.1177\/1758835920915299","article-title":"Second-line treatment in patients with advanced extra-pulmonary poorly differentiated neuroendocrine carcinoma: a systematic review and meta-analysis","volume":"12","author":"McNamara","year":"2020","journal-title":"Ther Adv Med Oncol"},{"key":"10.1016\/j.ctrv.2026.103195_bb0095","doi-asserted-by":"crossref","first-page":"529","DOI":"10.1097\/MPA.0000000000001529","article-title":"Efficacy of second-line chemotherapy in extrapulmonary neuroendocrine carcinoma","volume":"49","author":"McGarrah","year":"2020","journal-title":"Pancreas"},{"key":"10.1016\/j.ctrv.2026.103195_bb0100","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1007\/s12029-021-00800-0","article-title":"Comparative outcomes of second-line topoisomerase-I inhibitor therapies on neuroendocrine carcinoma","volume":"54","author":"Yeung","year":"2023","journal-title":"J Gastrointest Cancer"},{"key":"10.1016\/j.ctrv.2026.103195_bb0105","doi-asserted-by":"crossref","first-page":"297","DOI":"10.1016\/S1470-2045(23)00001-3","article-title":"Bevacizumab plus FOLFIRI after failure of platinum-etoposide first-line chemotherapy in patients with advanced neuroendocrine carcinoma (PRODIGE 41-BEVANEC): a randomised, multicentre, non-comparative, open-label, phase 2 trial","volume":"24","author":"Walter","year":"2023","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.ctrv.2026.103195_bb0110","doi-asserted-by":"crossref","first-page":"707","DOI":"10.1007\/s12020-021-02813-y","article-title":"Irinotecan-based chemotherapy in extrapulmonary neuroendocrine carcinomas: survival and safety data from a multicentric Italian experience","volume":"74","author":"Bardasi","year":"2021","journal-title":"Endocrine"},{"key":"10.1016\/j.ctrv.2026.103195_bb0115","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1530\/ERC-15-0075","article-title":"Post-first-line FOLFOX chemotherapy for grade 3 neuroendocrine carcinoma","volume":"22","author":"Hadoux","year":"2015","journal-title":"Endocr Relat Cancer"},{"key":"10.1016\/j.ctrv.2026.103195_bb0120","doi-asserted-by":"crossref","first-page":"134","DOI":"10.4103\/ejcrp.eJCRP-D-24-00032","article-title":"5-fluorouracil, leucovorin, oxaliplatin, and irinotecan as a potential standard for second-line therapy in extrapulmonary neuroendocrine carcinomas","volume":"11","author":"Ho","year":"2024","journal-title":"J Cancer Res Pract"},{"key":"10.1016\/j.ctrv.2026.103195_bb0125","doi-asserted-by":"crossref","first-page":"2290","DOI":"10.1158\/1078-0432.CCR-19-3356","article-title":"A phase II basket trial of dual anti\u2013CTLA-4 and anti\u2013PD-1 blockade in rare Tumors (DART SWOG 1609) in patients with nonpancreatic neuroendocrine Tumors","volume":"26","author":"Patel","year":"2020","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.ctrv.2026.103195_bb0130","doi-asserted-by":"crossref","DOI":"10.1038\/s41467-023-38611-5","article-title":"Durvalumab plus tremelimumab for the treatment of advanced neuroendocrine neoplasms of gastroenteropancreatic and lung origin","volume":"14","author":"Capdevila","year":"2023","journal-title":"Nat Commun"},{"key":"10.1016\/j.ctrv.2026.103195_bb0135","doi-asserted-by":"crossref","first-page":"1309","DOI":"10.1038\/s41416-020-0775-0","article-title":"Pembrolizumab monotherapy in patients with previously treated metastatic high-grade neuroendocrine neoplasms: joint analysis of two prospective, non-randomised trials","volume":"122","author":"Vijayvergia","year":"2020","journal-title":"Br J Cancer"},{"key":"10.1016\/j.ctrv.2026.103195_bb0140","doi-asserted-by":"crossref","first-page":"860","DOI":"10.1158\/1078-0432.CCR-24-2461","article-title":"Activity and safety of avelumab in high-grade neuroendocrine Tumors and poorly differentiated neuroendocrine carcinomas progressive after chemotherapy (AveNEC trial)","volume":"31","author":"Fottner","year":"2025","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.ctrv.2026.103195_bb0145","doi-asserted-by":"crossref","first-page":"498","DOI":"10.1530\/EC-20-0192","article-title":"Post first-line dacarbazine or temozolomide in neuroendocrine carcinoma","volume":"9","author":"Couronne","year":"2020","journal-title":"Endocr Connect"},{"key":"10.1016\/j.ctrv.2026.103195_bb0150","doi-asserted-by":"crossref","first-page":"4617","DOI":"10.1002\/cncr.26124","article-title":"Clinical effect of temozolomide-based chemotherapy in poorly differentiated endocrine carcinoma after progression on first-line chemotherapy","volume":"117","author":"Welin","year":"2011","journal-title":"Cancer"},{"key":"10.1016\/j.ctrv.2026.103195_bb0155","doi-asserted-by":"crossref","DOI":"10.1100\/2012\/170496","article-title":"Temozolomide as second or third line treatment of patients with neuroendocrine carcinomas","volume":"2012","author":"Olsen","year":"2012","journal-title":"ScientificWorldJournal"},{"key":"10.1016\/j.ctrv.2026.103195_bb0160","doi-asserted-by":"crossref","first-page":"2261","DOI":"10.1002\/cam4.807","article-title":"Efficacy of topotecan in pretreated metastatic poorly differentiated extrapulmonary neuroendocrine carcinoma","volume":"5","author":"Apostolidis","year":"2016","journal-title":"Cancer Med"},{"key":"10.1016\/j.ctrv.2026.103195_bb0165","doi-asserted-by":"crossref","DOI":"10.1634\/theoncologist.2019-0490","article-title":"An open-label, single-arm, two-stage, multicenter, phase II study to evaluate the efficacy of TLC388 and genomic analysis for poorly differentiated neuroendocrine carcinomas","volume":"25","author":"Chen","year":"2020","journal-title":"Oncologist"},{"key":"10.1016\/j.ctrv.2026.103195_bb0180","doi-asserted-by":"crossref","DOI":"10.3390\/jcm11051461","article-title":"Large cell neuroendocrine carcinoma of the lung: current understanding and challenges","volume":"11","author":"Andrini","year":"2022","journal-title":"J Clin Med"},{"key":"10.1016\/j.ctrv.2026.103195_bb0185","doi-asserted-by":"crossref","first-page":"8250","DOI":"10.1245\/s10434-022-12395-2","article-title":"Prognostic factors and survival in gastrointestinal extrapulmonary small cell carcinoma: a retrospective cohort study","volume":"29","author":"Ulanja","year":"2022","journal-title":"Ann Surg Oncol"},{"key":"10.1016\/j.ctrv.2026.103195_bb0190","doi-asserted-by":"crossref","DOI":"10.1530\/ERC-22-0206","article-title":"Expert consensus practice recommendations of the North American neuroendocrine tumor society for the management of high grade gastroenteropancreatic and gynecologic neuroendocrine neoplasms","volume":"30","author":"Eads","year":"2023","journal-title":"Endocr Relat Cancer"},{"key":"10.1016\/j.ctrv.2026.103195_bb0195","doi-asserted-by":"crossref","first-page":"1021","DOI":"10.1007\/s10555-023-10121-2","article-title":"Potent molecular-targeted therapies for gastro-entero-pancreatic neuroendocrine carcinoma","volume":"42","author":"Ooki","year":"2023","journal-title":"Cancer Metastasis Rev"},{"key":"10.1016\/j.ctrv.2026.103195_bb0200","doi-asserted-by":"crossref","DOI":"10.1111\/jne.12971","article-title":"Outcomes of small-cell versus large-cell gastroenteropancreatic neuroendocrine carcinomas: a population-based study","volume":"33","author":"Abdel-Rahman","year":"2021","journal-title":"J Neuroendocrinol"},{"key":"10.1016\/j.ctrv.2026.103195_bb0205","doi-asserted-by":"crossref","DOI":"10.3390\/jcm12186039","article-title":"Equivalent survival between gastric large-cell neuroendocrine carcinoma and gastric small-cell neuroendocrine carcinoma","volume":"12","author":"Li","year":"2023","journal-title":"J Clin Med"},{"key":"10.1016\/j.ctrv.2026.103195_bb0210","doi-asserted-by":"crossref","first-page":"437","DOI":"10.1097\/PAS.0000000000000169","article-title":"Poorly differentiated neuroendocrine carcinomas of the pancreas: a clinicopathologic analysis of 44 cases","volume":"38","author":"Basturk","year":"2014","journal-title":"Am J Surg Pathol"},{"key":"10.1016\/j.ctrv.2026.103195_bb0215","doi-asserted-by":"crossref","first-page":"457","DOI":"10.1159\/000528186","article-title":"Prognostic factors across poorly differentiated neuroendocrine neoplasms: a pooled analysis","volume":"113","author":"Centonze","year":"2022","journal-title":"Neuroendocrinology"},{"key":"10.1016\/j.ctrv.2026.103195_bb0220","doi-asserted-by":"crossref","first-page":"316","DOI":"10.1038\/s41416-025-03054-w","article-title":"Characteristics and treatment outcome in a prospective cohort of 639 advanced high-grade digestive neuroendocrine neoplasms (NET G3 and NEC). The NORDIC NEC 2 study","volume":"133","author":"Sorbye","year":"2025","journal-title":"Br J Cancer"},{"key":"10.1016\/j.ctrv.2026.103195_bb0225","doi-asserted-by":"crossref","first-page":"152","DOI":"10.1093\/annonc\/mds276","article-title":"Predictive and prognostic factors for treatment and survival in 305 patients with advanced gastrointestinal neuroendocrine carcinoma (WHO G3): the NORDIC NEC study","volume":"24","author":"Sorbye","year":"2013","journal-title":"Ann Oncol"},{"key":"10.1016\/j.ctrv.2026.103195_bb0230","first-page":"287","article-title":"From morphology to molecular targets\u2014the pathologist\u2019s view in diagnosing gastroenteropancreatic neuroendocrine neoplasms","volume":"15","author":"Henzinger","year":"2022","journal-title":"Memo Mag Eur Med Oncol"},{"key":"10.1016\/j.ctrv.2026.103195_bb0235","doi-asserted-by":"crossref","first-page":"616","DOI":"10.1159\/000503722","article-title":"Gastroenteropancreatic high-grade neuroendocrine neoplasms: histology and molecular analysis, two sides of the same coin","volume":"110","author":"Busico","year":"2020","journal-title":"Neuroendocrinology"},{"key":"10.1016\/j.ctrv.2026.103195_bb0240","doi-asserted-by":"crossref","DOI":"10.1093\/jnci\/djw277","article-title":"Design and validation of the GI-NEC score to prognosticate overall survival in patients with high-grade gastrointestinal neuroendocrine carcinomas","volume":"109","author":"Lamarca","year":"2017","journal-title":"J Natl Cancer Inst"},{"key":"10.1016\/j.ctrv.2026.103195_bb0245","doi-asserted-by":"crossref","DOI":"10.3332\/ecancer.2017.767","article-title":"Expression of ERCC1, Bcl-2, Lin28a, and Ki-67 as biomarkers of response to first-line platinum-based chemotherapy in patients with high-grade extrapulmonary neuroendocrine carcinomas or small cell lung cancer","volume":"11","author":"De M R\u00eago","year":"2017","journal-title":"eCancerMedicalScience"},{"key":"10.1016\/j.ctrv.2026.103195_bb0250","doi-asserted-by":"crossref","first-page":"4743","DOI":"10.1158\/1078-0432.CCR-24-0361","article-title":"YAP1 status defines two intrinsic subtypes of LCNEC with distinct molecular features and therapeutic vulnerabilities","volume":"30","author":"Stewart","year":"2024","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.ctrv.2026.103195_bb0255","doi-asserted-by":"crossref","first-page":"268","DOI":"10.1038\/s41698-024-00739-y","article-title":"Delta-like ligand 3 (DLL3) landscape in pulmonary and extra-pulmonary neuroendocrine neoplasms","volume":"8","author":"Serrano","year":"2024","journal-title":"NPJ Precis Oncol"},{"key":"10.1016\/j.ctrv.2026.103195_bb0260","doi-asserted-by":"crossref","DOI":"10.1007\/s12022-025-09854-3","article-title":"DLL3 expression in neuroendocrine carcinomas and neuroendocrine tumours: insights from a multicentric cohort of 1294 pulmonary and extrapulmonary neuroendocrine neoplasms","volume":"36","author":"Schmitt","year":"2025","journal-title":"Endocr Pathol"},{"key":"10.1016\/j.ctrv.2026.103195_bb0265","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1186\/s13045-023-01464-y","article-title":"Emerging therapies targeting the delta-like ligand 3 (DLL3) in small cell lung cancer","volume":"16","author":"Rudin","year":"2023","journal-title":"J Hematol Oncol"},{"key":"10.1016\/j.ctrv.2026.103195_bb0270","doi-asserted-by":"crossref","first-page":"166","DOI":"10.1016\/j.lungcan.2021.06.026","article-title":"YAP1 protein expression has variant prognostic significance in small cell lung cancer (SCLC) stratified by histological subtypes","volume":"160","author":"Wang","year":"2021","journal-title":"Lung Cancer"},{"key":"10.1016\/j.ctrv.2026.103195_bb0275","doi-asserted-by":"crossref","first-page":"318","DOI":"10.1158\/2767-9764.CRC-24-0501","article-title":"Expression patterns of DLL3 across neuroendocrine and non-neuroendocrine neoplasms reveal broad opportunities for therapeutic targeting","volume":"5","author":"Lozada","year":"2025","journal-title":"Cancer Res Commun"},{"key":"10.1016\/j.ctrv.2026.103195_bb0280","doi-asserted-by":"crossref","DOI":"10.1016\/j.labinv.2025.104093","article-title":"Molecular and immunohistochemical classification of extrapulmonary small cell neuroendocrine carcinomas: a study of 181 cases","volume":"105","author":"Pavl\u00ed\u010dkov\u00e1","year":"2025","journal-title":"Lab Investig"},{"key":"10.1016\/j.ctrv.2026.103195_bb0285","doi-asserted-by":"crossref","first-page":"388","DOI":"10.1007\/s12022-022-09722-4","article-title":"Molecular subtypes of extra-pulmonary neuroendocrine carcinomas identified by the expression of neuroendocrine lineage-specific transcription factors","volume":"33","author":"Metovic","year":"2022","journal-title":"Endocr Pathol"},{"key":"10.1016\/j.ctrv.2026.103195_bb0290","doi-asserted-by":"crossref","first-page":"3522","DOI":"10.1245\/s10434-022-11477-5","article-title":"Surgical treatment of patients with poorly differentiated pancreatic neuroendocrine carcinoma: an NCDB analysis","volume":"29","author":"Kaslow","year":"2022","journal-title":"Ann Surg Oncol"},{"key":"10.1016\/j.ctrv.2026.103195_bb0295","doi-asserted-by":"crossref","first-page":"1373","DOI":"10.1002\/jso.26644","article-title":"Surgical resection of high-grade nonfunctional pancreatic neuroendocrine carcinoma is associated with improved survival","volume":"124","author":"Jiang","year":"2021","journal-title":"J Surg Oncol"},{"key":"10.1016\/j.ctrv.2026.103195_bb0300","unstructured":"Zhou Y, Ijioma S, Liu N, Boerner T, Koevi J, Pereira F, et al. Exploring symptoms, impacts, and bothersomeness in patients with extrapulmonary neuroendocrine carcinoma (epNEC) [congress abstract H25]. European Neuroendocrine Tumor Society (ENETS) Abstract Booklet 2026:158."},{"key":"10.1016\/j.ctrv.2026.103195_bb0305","article-title":"Evaluation of healthcare resource utilization and costs among patients diagnosed with extra-pulmonary neuroendocrine carcinoma (epNEC): a non-interventional multimodal database analysis in the US [poster abstract]","volume":"32","author":"Gay","year":"2026","journal-title":"J Manag Care Spec Pharm"},{"key":"10.1016\/j.ctrv.2026.103195_bb0310","doi-asserted-by":"crossref","first-page":"1076","DOI":"10.1634\/theoncologist.2018-0604","article-title":"Current treatment options in Gastroenteropancreatic neuroendocrine carcinoma","volume":"24","author":"Thomas","year":"2019","journal-title":"Oncologist"},{"key":"10.1016\/j.ctrv.2026.103195_bb0315","article-title":"Gastroenteropancreatic neuroendocrine tumors\u2014current status and advances in diagnostic imaging","volume":"13","author":"Vogele","year":"2023","journal-title":"Diagnostics (Basel)"},{"key":"10.1016\/j.ctrv.2026.103195_bb0320","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1007\/s12022-024-09807-2","article-title":"Molecular classification of gastrointestinal and pancreatic neuroendocrine neoplasms: are we ready for that?","volume":"35","author":"Uccella","year":"2024","journal-title":"Endocr Pathol"},{"key":"10.1016\/j.ctrv.2026.103195_bb0325","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1530\/ERC-21-0152","article-title":"The molecular characteristics of high-grade gastroenteropancreatic neuroendocrine neoplasms","volume":"29","author":"Venizelos","year":"2022","journal-title":"Endocr Relat Cancer"},{"key":"10.1016\/j.ctrv.2026.103195_bb0330","doi-asserted-by":"crossref","first-page":"3287","DOI":"10.1038\/s41598-025-86237-y","article-title":"Exploring the expression of DLL3 in gastroenteropancreatic neuroendocrine neoplasms and its potential diagnostic value","volume":"15","author":"Yin","year":"2025","journal-title":"Sci Rep"},{"key":"10.1016\/j.ctrv.2026.103195_bb0335","doi-asserted-by":"crossref","DOI":"10.1200\/EDBK-26-518934","article-title":"Evolving therapeutic strategies in neuroendocrine neoplasms: a new era of personalized therapies","volume":"46","author":"Grewal","year":"2026","journal-title":"Am Soc Clin Oncol Educ Book"},{"key":"10.1016\/j.ctrv.2026.103195_bb0340","doi-asserted-by":"crossref","first-page":"3021","DOI":"10.1200\/JCO-25-00363","article-title":"Phase I dose-escalation results for the Delta-like ligand 3\/CD3 IgG-like T-cell engager Obrixtamig (BI 764532) in patients with Delta-like ligand 3+ small cell lung Cancer or neuroendocrine carcinomas","volume":"43","author":"Wermke","year":"2025","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ctrv.2026.103195_bb0345","doi-asserted-by":"crossref","first-page":"2639","DOI":"10.2217\/fon-2022-0196","article-title":"Phase I trial of the DLL3\/CD3 bispecific T-cell engager BI 764532 in DLL3-positive small-cell lung cancer and neuroendocrine carcinomas","volume":"18","author":"Wermke","year":"2022","journal-title":"Future Oncol"},{"key":"10.1016\/j.ctrv.2026.103195_bb0350","doi-asserted-by":"crossref","first-page":"5258","DOI":"10.1158\/1078-0432.CCR-20-0926","article-title":"A bispecific DLL3\/CD3 IgG-like T-cell engaging antibody induces antitumor responses in small cell lung Cancer","volume":"26","author":"Hipp","year":"2020","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.ctrv.2026.103195_bb0355","unstructured":"ClinicalTrials.gov. DAREON\u00ae-NEC-1: A Study in People With Advanced Extrapulmonary Neuroendocrine Cancer to Compare Obrixtamig Plus Carboplatin and Etoposide Treatment With Standard Chemotherapy. NCT07544654., https:\/\/clinicaltrials.gov\/study\/NCT07544654. Accessed July 9, 2026."},{"key":"10.1016\/j.ctrv.2026.103195_bb0360","unstructured":"ClinicalTrials.gov. A Study of Peluntamig (PT217) in Patients With Neuroendocrine Carcinomas Expressing DLL3 (the SKYBRIDGE Study). NCT05652686., https:\/\/clinicaltrials.gov\/study\/NCT05652686. Accessed July 9, 2026."},{"key":"10.1016\/j.ctrv.2026.103195_bb0365","article-title":"656\u00a0a phase 1\/2 trial in progress of MK-6070 (aka HPN328), a DLL3-targeting T cell engager, as monotherapy or combination therapy for advanced cancers associated with DLL3 expression","author":"Jain","year":"2024","journal-title":"J Immunother Cancer"},{"key":"10.1016\/j.ctrv.2026.103195_bb0370","doi-asserted-by":"crossref","first-page":"8090","DOI":"10.1200\/JCO.2024.42.16_suppl.8090","article-title":"Updated results from a phase 1\/2 study of HPN328, a tri-specific, half-life (T1\/2) extended DLL3-targeting T-cell engager in patients (pts) with small cell lung cancer (SCLC) and other neuroendocrine cancers (NEC)","volume":"42","author":"Beltran","year":"2024","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ctrv.2026.103195_bb0375","doi-asserted-by":"crossref","first-page":"1294","DOI":"10.1158\/1535-7163.MCT-23-0524","article-title":"HPN328, a Trispecific T cell-activating protein construct targeting DLL3-expressing solid Tumors","volume":"23","author":"Molloy","year":"2024","journal-title":"Mol Cancer Ther"},{"key":"10.1016\/j.ctrv.2026.103195_bb0380","unstructured":"ClinicalTrials.gov. A Study of ZG006 for Injection Versus Investigator-Selected Chemotherapy in Participants With Advanced Neuroendocrine Carcinoma. NCT07595913., https:\/\/clinicaltrials.gov\/study\/NCT07595913. Accessed July 10, 2026."},{"key":"10.1016\/j.ctrv.2026.103195_bb0385","unstructured":"ClinicalTrials.gov. Dose Escalation Study of ZG006 in Participants With Advanced Small Cell Lung Cancer or Neuroendocrine Carcinoma, Followed by Dose Expansion Study in Participants With Advanced Small Cell Lung Cancer. NCT06283719., https:\/\/clinicaltrials.gov\/study\/NCT06283719. Accessed July 10, 2026."},{"key":"10.1016\/j.ctrv.2026.103195_bb0400","unstructured":"ClinicalTrials.gov. ZG006 and ZG005 in Participants With Small Cell Lung Cancer or Neuroendocrine Carcinoma. NCT07038096., https:\/\/clinicaltrials.gov\/study\/NCT07038096. Accessed July 10, 2026."},{"key":"10.1016\/j.ctrv.2026.103195_bb0405","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1158\/1078-0432.CCR-17-1921","article-title":"Molecular subtypes of pulmonary large-cell neuroendocrine carcinoma predict chemotherapy treatment outcome","volume":"24","author":"Derks","year":"2018","journal-title":"Clin Cancer Res"}],"container-title":["Cancer Treatment Reviews"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S030573722600109X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S030573722600109X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,9,6]],"date-time":"2026-09-06T22:30:16Z","timestamp":1788733816000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S030573722600109X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9]]},"references-count":77,"alternative-id":["S030573722600109X"],"URL":"https:\/\/doi.org\/10.1016\/j.ctrv.2026.103195","relation":{},"ISSN":["0305-7372"],"issn-type":[{"value":"0305-7372","type":"print"}],"subject":[],"published":{"date-parts":[[2026,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Understanding extrapulmonary neuroendocrine carcinomas: Survival, prognosis, and patient quality of life","name":"articletitle","label":"Article Title"},{"value":"Cancer Treatment Reviews","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ctrv.2026.103195","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Authors. Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}],"article-number":"103195"}}